Literature DB >> 20068163

Drug combination studies and their synergy quantification using the Chou-Talalay method.

Ting-Chao Chou1.   

Abstract

This brief perspective article focuses on the most common errors and pitfalls, as well as the do's and don'ts in drug combination studies, in terms of experimental design, data acquisition, data interpretation, and computerized simulation. The Chou-Talalay method for drug combination is based on the median-effect equation, derived from the mass-action law principle, which is the unified theory that provides the common link between single entity and multiple entities, and first order and higher order dynamics. This general equation encompasses the Michaelis-Menten, Hill, Henderson-Hasselbalch, and Scatchard equations in biochemistry and biophysics. The resulting combination index (CI) theorem of Chou-Talalay offers quantitative definition for additive effect (CI = 1), synergism (CI < 1), and antagonism (CI > 1) in drug combinations. This theory also provides algorithms for automated computer simulation for synergism and/or antagonism at any effect and dose level, as shown in the CI plot and isobologram, respectively.

Mesh:

Substances:

Year:  2010        PMID: 20068163     DOI: 10.1158/0008-5472.CAN-09-1947

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  1879 in total

1.  Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.

Authors:  Yijun Zhang; James H Chapman; Asim Ulcay; Richard E Sutton
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.

Authors:  Pei-Chih Lee; Rajesh Kakadiya; Tsann-Long Su; Te-Chang Lee
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

3.  Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Authors:  Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran
Journal:  Neuro Oncol       Date:  2014-11-12       Impact factor: 12.300

4.  The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.

Authors:  Daniel R Budman; Julia Tai; Anthony Calabro; Veena John
Journal:  Invest New Drugs       Date:  2010-06-09       Impact factor: 3.850

5.  BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.

Authors:  Heike Niessner; Tobias Sinnberg; Corinna Kosnopfel; Keiran S M Smalley; Daniela Beck; Christian Praetorius; Marion Mai; Stefan Beissert; Dagmar Kulms; Martin Schaller; Claus Garbe; Keith T Flaherty; Dana Westphal; Ines Wanke; Friedegund Meier
Journal:  Clin Cancer Res       Date:  2017-07-19       Impact factor: 12.531

6.  Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

Authors:  George Au-Yeung; Franziska Lang; Walid J Azar; Chris Mitchell; Kate E Jarman; Kurt Lackovic; Diar Aziz; Carleen Cullinane; Richard B Pearson; Linda Mileshkin; Danny Rischin; Alison M Karst; Ronny Drapkin; Dariush Etemadmoghadam; David D L Bowtell
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

7.  Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition.

Authors:  Raymond Wu; Ramachandran Murali; Yasuaki Kabe; Samuel W French; Yi-Ming Chiang; Siyu Liu; Linda Sher; Clay C Wang; Stan Louie; Hidekazu Tsukamoto
Journal:  Hepatology       Date:  2018-10-09       Impact factor: 17.425

8.  Effects of miconazole/clotrimazole and praziquantel combinations against the liver fluke Opisthorchis felineus in vivo and in vitro.

Authors:  Maria Y Pakharukova; Yuri V Pakharukov; Viatcheslav A Mordvinov
Journal:  Parasitol Res       Date:  2018-05-02       Impact factor: 2.289

9.  Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Authors:  Zhenyong Keck; Wenyan Wang; Yong Wang; Patrick Lau; Thomas H R Carlsen; Jannick Prentoe; Jinming Xia; Arvind H Patel; Jens Bukh; Steven K H Foung
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

10.  Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.

Authors:  Robert L Dilley; Weijie Poh; Douglas E Gladstone; James G Herman; Margaret M Showel; Judith E Karp; Michael A McDevitt; Keith W Pratz
Journal:  Leuk Res       Date:  2013-12-30       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.